Yarrow Bioscience, Inc. (NasdaqCM: YARW)
Health Care · Biotechnology · US
$19.63
+8.75% today · +6.3% 1Y
Yarrow Bioscience, Inc. (NasdaqCM: YARW) operates in the Biotechnology industry within the Health Care sector. The company is valued at $182.64M and employs 10 people.
Over the last twelve months the share price has gained 6.3%, trading between 13.60 and 46.95.
Tweenvest scores Yarrow Bioscience, Inc. across four factors: quality 77/100, value 80/100. Its strongest factor is value.
YARW price history
Key figures
- Market cap
- $182.64M
- Revenue (TTM)
- —
- P/E
- -0.64
- EPS
- -66.82
- Dividend yield
- —
- Beta (5Y)
- 2.13
- 52-week high
- $46.95
- 52-week low
- $13.60
- Avg volume (3M)
- —
- Shares outstanding
- 9.30M
- Employees
- 10
- Next earnings
- —
About Yarrow Bioscience, Inc.
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
- ISIN
- US92941V4077
- Founded
- 2025
- Listed since
- Jul 28, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.NasdaqGM: ARTV | $186.36M | $3.92 | +3.95% |
| Entrada Therapeutics, Inc.NasdaqGM: TRDA | $185.82M | $5.09 | -1.55% |
| Anika Therapeutics, Inc.NasdaqGS: ANIK | $184.99M | $13.81 | -1.00% |
| Whitehawk Therapeutics, Inc.NasdaqCM: WHWK | $184.70M | $3.13 | +1.62% |
| TYK Medicines, IncSEHK: 2410 | $182.64M | HK$3.73 | -9.15% |
| Thor Medical ASAOB: TRMED | $179.44M | Nkr4.06 | -0.98% |
| Eledon Pharmaceuticals, Inc.NasdaqCM: ELDN | $178.80M | $2.12 | -10.57% |
| Healios K.K.TSE: 4593 | $178.72M | ¥210.00 | +1.94% |